Purpura

·MeSH: Purpura

21 drugs in development·10 companies·2 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Promacta	Royalty Pharma plc (RPRX)

Phase 3(10)

Drug	Company
anti-cd20 antibody	Sanofi (SNY)
hbm9161 dose a	Q BioMed Inc. (QBIO)
hbm9161 dose b	Q BioMed Inc. (QBIO)
mezagitamab	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
mezagitamab	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
prn1008	Principia Biopharma Inc. (PRNB)
recombinant adamts13	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-755	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-755	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-755	SHIRE PLC (SHPGF)

Phase 2(3)

Drug	Company
eltrombopag	Novartis AG (NVS)
Eltrombopag	Novartis AG (NVS)
tak-755	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 1/Phase 2(4)

Drug	Company
biological	MOMENTA PHARMACEUTICALS INC (MNTA)
intravenous immunoglobulin	MOMENTA PHARMACEUTICALS INC (MNTA)
m254	MOMENTA PHARMACEUTICALS INC (MNTA)
zugo-cel	CRISPR Therapeutics AG (CRSP)

Phase 2/Phase 3(3)

Drug	Company
caplacizumab	Sanofi (SNY)
immunosuppressive treatment (eg	Sanofi (SNY)
plasma exchange	Sanofi (SNY)

BioSniper tracks 21 drugs in development for Purpura across 10 companies.

There are 2 clinical trials targeting Purpura tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.